Intercept Pharmaceuticals, Inc. (ICPT) At $61.16 Forms Bottom; Newlink Genetics (NLNK) Shorts Up By 14.75%

February 18, 2018 - By Martha Paddon

Newlink Genetics Corporation (NASDAQ:NLNK) had an increase of 14.75% in short interest. NLNK’s SI was 7.26M shares in February as released by FINRA. Its up 14.75% from 6.33M shares previously. With 987,500 avg volume, 7 days are for Newlink Genetics Corporation (NASDAQ:NLNK)’s short sellers to cover NLNK’s short positions. The SI to Newlink Genetics Corporation’s float is 36.94%. The stock increased 3.95% or $0.27 during the last trading session, reaching $7.11. About 701,914 shares traded. NewLink Genetics Corporation (NASDAQ:NLNK) has risen 49.90% since February 18, 2017 and is uptrending. It has outperformed by 33.20% the S&P500.

Intercept Pharmaceuticals, Inc. (ICPT) formed multiple bottom with $55.66 target or 9.00% below today’s $61.16 share price. Intercept Pharmaceuticals, Inc. (ICPT) has $1.54B valuation. The stock increased 0.86% or $0.52 during the last trading session, reaching $61.16. About 714,838 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 14.52% since February 18, 2017 and is downtrending. It has underperformed by 31.22% the S&P500.

Among 6 analysts covering NewLink Genetics (NASDAQ:NLNK), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NewLink Genetics had 15 analyst reports since March 23, 2016 according to SRatingsIntel. The firm has “Hold” rating by Jefferies given on Thursday, August 24. The stock of NewLink Genetics Corporation (NASDAQ:NLNK) earned “Outperform” rating by Robert W. Baird on Friday, September 8. As per Wednesday, May 11, the company rating was downgraded by SunTrust. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, August 31. The firm has “Outperform” rating by Robert W. Baird given on Wednesday, March 23. The rating was maintained by Jefferies with “Hold” on Thursday, June 8. The stock of NewLink Genetics Corporation (NASDAQ:NLNK) has “Buy” rating given on Friday, October 13 by Robert W. Baird. Stifel Nicolaus maintained it with “Buy” rating and $1400 target in Monday, July 10 report. The stock of NewLink Genetics Corporation (NASDAQ:NLNK) earned “Buy” rating by Cantor Fitzgerald on Sunday, June 4. Jefferies maintained it with “Buy” rating and $25 target in Friday, November 3 report.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $263.62 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

Investors sentiment increased to 1.22 in Q3 2017. Its up 0.28, from 0.94 in 2017Q2. It increased, as 15 investors sold NewLink Genetics Corporation shares while 30 reduced holdings. 25 funds opened positions while 30 raised stakes. 18.44 million shares or 16.63% more from 15.81 million shares in 2017Q2 were reported. Canada Pension Plan Board owns 20,800 shares for 0% of their portfolio. Bridgeway Cap Mgmt has invested 0.01% in NewLink Genetics Corporation (NASDAQ:NLNK). Retail Bank Of Mellon reported 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). Invesco Ltd stated it has 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). Bankshares Of Montreal Can holds 0% or 65,958 shares. Barclays Public Ltd Co has 82,814 shares for 0% of their portfolio. Rhumbline Advisers holds 0% or 25,326 shares in its portfolio. Moreover, Proshare Advisors Ltd has 0% invested in NewLink Genetics Corporation (NASDAQ:NLNK). Northern Tru Corporation reported 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Spark Invest Mgmt Ltd Liability Co holds 0.05% or 85,400 shares. California-based Schwab Charles Invest has invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Legal & General Gp Public holds 5,412 shares or 0% of its portfolio. Goldman Sachs Gru reported 48,915 shares stake. Stifel Fin holds 39,700 shares or 0% of its portfolio. Royal Fincl Bank Of Canada holds 0% or 2,789 shares in its portfolio.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on February, 22. They expect $-3.39 earnings per share, up 29.96% or $1.45 from last year’s $-4.84 per share. After $-2.89 actual earnings per share reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 17.30% negative EPS growth.